Workflow
OmniVision Integrated Circuits Group(603501)
icon
Search documents
港股IPO动态:今日豪威集团上市
Jin Rong Jie· 2026-01-11 22:28
今日豪威集团(0501.HK)上市,无新股申购。 本文源自:金融界AI电报 ...
豪威集团(0501)全球发售募资47.99亿港元 基石投资者认购占比45.28% 拟于2026...
Xin Lang Cai Jing· 2026-01-09 15:28
来源:新浪港股-好仓工作室 豪威集成电路(集团)股份有限公司(股份代号:0501,简称"豪威集团")发布全球发售结果公告,最终 确定本次全球发售的发行价为每股H股104.80港元。本次全球发售的基础发行股份数目为45,800,000股H 股,其中香港发售股份4,580,000股,国际发售股份41,220,000股(视乎超额配售权行使情况而定)。超 额配售权相关的超额分配股份数目为6,870,000股,该部分可通过行使超额配售权、二级市场购买或递延 交付等方式补足。 根据最终发行价计算,本次全球发售所得款项总额约为47.998亿港元,扣除预计应付上市开支1.067亿港 元后,所得款项净额约为46.932亿港元。 认购情况方面,香港公开发售部分有效申请数目为14,551份,认购倍数达9.28倍;国际发售部分认购倍 数为9.73倍,承配人总数为127名。由于香港公开发售未触发回补机制,回拨情况不适用,最终香港发 售股份仍为4,580,000股,占全球发售股份总数的10%;国际发售股份为41,220,000股,占比90%。 基石投资者阵容方面,本次全球发售共有10名基石投资者参与,合计认购20,740,200股H股, ...
豪威集团:香港公开发售获9.28倍认购 每股发售价104.8港元
Zhi Tong Cai Jing· 2026-01-09 15:02
Group 1 - The company,豪威集团, announced the results of its global offering, issuing 45.8 million H-shares, with 10% allocated for public offering in Hong Kong and 90% for international offering [1] - The offer price per share was set at HKD 104.8, resulting in net proceeds of approximately HKD 4.693 billion from the global offering [1] - The Hong Kong public offering was oversubscribed by 9.28 times, while the international offering was oversubscribed by 9.73 times [1] Group 2 - The H-shares are expected to commence trading on the Hong Kong Stock Exchange at 9:00 AM on January 12, 2026 [1]
豪威集团(00501):香港公开发售获9.28倍认购 每股发售价104.8港元
智通财经网· 2026-01-09 14:59
智通财经APP讯,豪威集团(00501)公布配发结果,公司全球发售4580万股H股,香港公开发售占10%, 国际发售占90%。每股发售价104.8港元,全球发售净筹约46.93亿港元。每手100股,预期H股将于2026 年1月12日上午九时正开始在联交所买卖。 其中,香港公开发售获9.28倍认购,国际发售获9.73倍认购。 ...
豪威集团(00501.HK)香港公开发售获9.28倍认购 1月12日上市
Ge Long Hui· 2026-01-09 14:58
假设全球发售于2026年1月12日(星期一)上午八时正(香港时间)或之前成为无条件,则预期H股将于2026 年1月12日(星期一)上午九时正(香港时间)开始在联交所买卖。H股买卖单位为每手100股H股,H股股份 代号为0501。 格隆汇1月9日丨豪威集团(00501.HK)公告,公司全球发售45,800,000股H股,每股H股104.80港元,所得 款项净额46.93亿港元。香港公开发售股份数目占全球发售股份数目10.00%,获认购9.28倍;国际发售 股份数目占全球发售股份90.00%,获认购倍9.73倍。 ...
豪威集团H股公开发行价格确定,预计1月12日港交所挂牌
Ju Chao Zi Xun· 2026-01-09 03:18
Group 1 - The core announcement is regarding the public offering price and listing arrangements for the H-shares of the company, which is set at HKD 104.8 per share [2] - The H-shares are intended for subscription by qualified foreign investors, domestic securities firms authorized for overseas securities investment, qualified domestic institutional investors, and other regulatory-compliant investors [2] - The company has completed the filing for its H-share issuance with the China Securities Regulatory Commission, and the listing application has been reviewed by the Hong Kong Stock Exchange [2] Group 2 - The H-shares are expected to be listed and commence trading on the Hong Kong Stock Exchange on January 12, 2026 [3]
豪威集团大宗交易成交1.85万股 成交额215.65万元
Group 1 - The core transaction of Haowei Group on January 8 involved a block trade of 18,500 shares, amounting to 2.1565 million yuan, with a transaction price of 116.57 yuan, representing an 11.60% discount compared to the closing price of the day [1][2] - The buyer and seller of the block trade were both from the same brokerage, CITIC Securities (Shandong) Co., Ltd., located in the Qingdao West Coast New Area [1][2] - Over the past three months, Haowei Group has recorded a total of 8 block trades, with a cumulative transaction amount of 102 million yuan [1] Group 2 - The latest margin financing balance for Haowei Group is 5.072 billion yuan, showing a decrease of 36.2231 million yuan over the past five days, which is a decline of 0.71% [2] - On the same day, Haowei Group's closing price was 131.86 yuan, reflecting an increase of 1.81%, with a turnover rate of 1.68% and a total trading volume of 2.679 billion yuan [1][2] - The net inflow of main funds for the day was 181 million yuan, while the cumulative net outflow over the past five days was 28.7198 million yuan [1]
【财闻联播】万科宣布:郁亮退休,辞去全部职务!摩尔线程,最新发布
券商中国· 2026-01-08 12:47
Macro Dynamics - The Chinese Foreign Ministry warns that Japan's growing nuclear ambitions pose a serious threat to global peace and stability, urging Japan to clarify its stance on nuclear weapons and adhere to international treaties [2] Company Dynamics - Vanke A announces the resignation of its executive vice president, Yu Liang, due to retirement age, effective January 8, 2026 [10] - Moore Threads releases version 1.1 of its open-source distributed training simulation tool, SimuMax, enhancing its capabilities for large model training [11] - Hao Wei Group sets the final price for its H-share issuance at HKD 104.80 per share, expected to be listed on January 12, 2026 [13][14] - Wens Foodstuff Group forecasts a significant decline in net profit for 2025, estimating a drop of 40.73% to 46.12% year-on-year due to falling pig prices despite stable production management [15] - Jinli Permanent Magnet anticipates a substantial increase in net profit for 2025, projecting a growth of 127% to 161% year-on-year, driven by its applications in various industries including new energy vehicles and robotics [16] Market Data - The Shanghai Composite Index fell by 0.07%, while the Shenzhen Component and ChiNext Index dropped by 0.51% and 0.82% respectively, with significant activity in the commercial aerospace sector [7] - As of January 7, the financing balance on the Shanghai Stock Exchange reached CNY 12,982.15 billion, an increase of CNY 123.16 billion from the previous trading day [8] - The Hang Seng Index declined by 1.17%, with technology stocks underperforming, while the semiconductor sector saw gains [9] Regulatory Updates - The Ministry of Commerce emphasizes that companies engaging in foreign investments and technology exports must comply with Chinese laws and regulations, particularly in the context of Meta's acquisition of Manus [3] - The State Administration for Market Regulation addresses potential monopoly risks in the polysilicon market, leading to a significant drop in polysilicon futures prices [12] Urban Development - Guangzhou issues a plan to accelerate the development of advanced manufacturing, aiming to double industrial added value by 2035 and focusing on strategic industry clusters [4]
豪威集团:关于“韦尔转债”预计满足转股价格修正条件的提示性公告
Group 1 - The core point of the article is that Haowei Group announced a potential downward adjustment of the conversion price for its "Weier Convertible Bonds" due to its stock closing price being below 85% of the current conversion price for ten consecutive trading days as of January 8, 2026 [1] - According to the regulations from the Shanghai Stock Exchange, if the adjustment conditions are triggered, the company will convene a board meeting on the same day to decide whether to adjust the conversion price and will fulfill its information disclosure obligations promptly [1]
1月8日晚间重要公告一览
Xi Niu Cai Jing· 2026-01-08 10:30
Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]